# US 2023/0364212 A1 · Compositions and method for optimized peptide vaccines using residue optimization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0364212 A1
- Document ID: US20230364212A1
- Status: Published application
- Kind: A1
- Application number: 18/170,994
- Filed: 2023-02-17
- Published: 2023-11-16
- Earliest claimed: 2021-04-28
- Assignees: Think Therapeutics, Inc.
- Applicants: Think Therapeutics, Inc.
- Inventors: David Kenneth GIFFORD; Brandon CARTER
- Web page: https://patentgrep.com/patent/US20230364212A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001104: {Epidermal growth factor receptors [EGFR]}
- A61K 39/001151: {p53}
- A61K 39/001152: {Transcription factors, e.g. SOX or c-MYC}
- A61K 39/001158: {Proteinases}
- A61K 39/00116: {Serine proteases, e.g. kallikrein}
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/572: {cytotoxic response}
- A61K 2039/70: {Multivalent vaccine}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2039/812: {Breast}
- A61K 2039/82: {Colon}
- A61K 2039/852: {Pancreas}
- A61K 2039/86: {Lung}
- A61K 2039/876: {Skin, melanoma}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

## Claims

### Claim 1

An immunogenic composition comprising nucleic acid sequences encoding at least one amino acid sequence selected from the group consisting of SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 7882, SEQ ID NO: 7884, SEQ ID NO: 7887, SEQ ID NO: 7888, SEQ ID NO: 7894, SEQ ID NO: 7920, SEQ ID NO: 7921, SEQ ID NO: 7933, SEQ ID NO: 7934, SEQ ID NO: 7940, SEQ ID NO: 7950, SEQ ID NO: 7951, SEQ ID NO: 7970, SEQ ID NO: 7972, SEQ ID NO: 7976, SEQ ID NO: 7982, SEQ ID NO: 8139, SEQ ID NO: 8267, SEQ ID NO: 8269, SEQ ID NO: 8272, SEQ ID NO: 8277, SEQ ID NO: 8296, and SEQ ID NO: 8422.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the nucleic acid sequences are contained in a construct for in vivo expression of one or more peptides encoded by the nucleic acid sequences.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, wherein an administration of the nucleic acid sequences causes the one or more peptides encoded by the nucleic acid sequences to be displayed by an HLA class I molecule in a subject.

### Claim 4 (depends on 2)

The immunogenic composition of claim 2, wherein the nucleic acid sequences are contained in a construct for the in vivo expression of at least two peptides encoded by the nucleic acid sequences, wherein an administration of the nucleic acid sequences causes:
a first peptide of the at least two peptides to be displayed by a first plurality of HLA class I alleles; and
a second peptide of the at least two peptides to be displayed by a second plurality of HLA class I alleles,
wherein the first plurality of HLA class I alleles and the second plurality of HLA class I alleles differ by at least one HLA class I allele.

### Claim 5 (depends on 3)

The immunogenic composition of claim 3, wherein the at least one amino acid sequence comprises two heteroclitic modifications of a fragment of a KRAS protein containing a KRAS G12C mutation.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein the at least one amino acid sequence is selected based on a HLA class I allele that is expressed in a subject.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein the nucleic acid sequences encode at least one amino acid sequence selected from the group consisting of SEQ ID NO: 158, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 7921, SEQ ID NO: 7933, SEQ ID NO: 7950, SEQ ID NO: 7951, SEQ ID NO: 7976, SEQ ID NO: 8080, SEQ ID NO: 8272, SEQ ID NO: 8296, and SEQ ID NO: 8422.

### Claim 8

An immunogenic composition comprising nucleic acid sequences encoding at least one amino acid sequence selected from the group consisting of SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 11018, SEQ ID NO: 11021, SEQ ID NO: 11024, SEQ ID NO: 11030, SEQ ID NO: 11053, SEQ ID NO: 11054, SEQ ID NO: 11064, SEQ ID NO: 11072, SEQ ID NO: 11073, SEQ ID NO: 11078, SEQ ID NO: 11079, SEQ ID NO: 11080, SEQ ID NO: 11092, SEQ ID NO: 11094, SEQ ID NO: 11097, SEQ ID NO: 11102, SEQ ID NO: 11106, SEQ ID NO: 11108, SEQ ID NO: 11116, SEQ ID NO: 11118, SEQ ID NO: 11122, SEQ ID NO: 11128, SEQ ID NO: 11130, SEQ ID NO: 11193, SEQ ID NO: 11203, SEQ ID NO: 11206, SEQ ID NO: 11212, SEQ ID NO: 11220, SEQ ID NO: 11227, SEQ ID NO: 11274, SEQ ID NO: 11283, SEQ ID NO: 11305, SEQ ID NO: 11306, SEQ ID NO: 11310, SEQ ID NO: 11311, SEQ ID NO: 11315, SEQ ID NO: 11324, SEQ ID NO: 11333, SEQ ID NO: 11342, SEQ ID NO: 11343, SEQ ID NO: 11352, SEQ ID NO: 11447, SEQ ID NO: 11453, SEQ ID NO: 11456, SEQ ID NO: 11457, SEQ ID NO: 11461, SEQ ID NO: 11465, SEQ ID NO: 11468, SEQ ID NO: 11469, SEQ ID NO: 11474, SEQ ID NO: 11585, SEQ ID NO: 11617, SEQ ID NO: 11672, SEQ ID NO: 11701, SEQ ID NO: 11723, and SEQ ID NO: 11734.

### Claim 9 (depends on 8)

The immunogenic composition of claim 8, wherein the nucleic acid sequences are contained in a construct for in vivo expression of one or more peptides encoded by the nucleic acid sequences.

### Claim 10 (depends on 9)

The immunogenic composition of claim 9, wherein an administration of the nucleic acid sequences causes the one or more peptides encoded by the nucleic acid sequences to be displayed by an HLA class I molecule in a subject.

### Claim 11 (depends on 9)

The immunogenic composition of claim 9, wherein the nucleic acid sequences are contained in a construct for the in vivo expression of at least two peptides encoded by the nucleic acid sequences, wherein an administration of the nucleic acid sequences causes:
a first peptide of the at least two peptides to be displayed by a first plurality of HLA class I alleles; and
a second peptide of the at least two peptides to be displayed by a second plurality of HLA class I alleles,
wherein the first plurality of HLA class I alleles and the second plurality of HLA class I alleles differ by at least one HLA class I allele.

### Claim 12 (depends on 10)

The immunogenic composition of claim 10, wherein the at least one amino acid sequence comprises two heteroclitic modifications of a fragment of a KRAS protein containing a KRAS G12V mutation.

### Claim 13 (depends on 8)

The immunogenic composition of claim 8, wherein the at least one amino acid sequence is selected based on a HLA class I allele that is expressed in a subject.

### Claim 14 (depends on 8)

The immunogenic composition of claim 8, wherein the nucleic acid sequences encode at least one amino acid sequence selected from the group consisting of SEQ ID NO: 210, SEQ ID NO: 11018, SEQ ID NO: 11054, SEQ ID NO: 11078, SEQ ID NO: 11080, SEQ ID NO: 11118, SEQ ID NO: 11122, SEQ ID NO: 11128, SEQ ID NO: 11130, SEQ ID NO: 11310, SEQ ID NO: 11447, SEQ ID NO: 11468, SEQ ID NO: 11469, and SEQ ID NO: 11474.

### Claim 15 (depends on 11)

The immunogenic composition of claim 11, wherein the nucleic acid sequences encode at least two amino acid sequences selected from the group consisting of SEQ ID NO: 210, SEQ ID NO: 11018, SEQ ID NO: 11054, SEQ ID NO: 11078, SEQ ID NO: 11080, SEQ ID NO: 11118, SEQ ID NO: 11122, SEQ ID NO: 11128, SEQ ID NO: 11130, SEQ ID NO: 11310, SEQ ID NO: 11447, SEQ ID NO: 11468, SEQ ID NO: 11469, and SEQ ID NO: 11474.

### Claim 16

An immunogenic composition comprising nucleic acid sequences encoding at least one amino acid sequence selected from the group consisting of SEQ ID NO: 183, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 9760, SEQ ID NO: 9768, SEQ ID NO: 9771, SEQ ID NO: 9772, SEQ ID NO: 9775, SEQ ID NO: 9776, SEQ ID NO: 9779, SEQ ID NO: 9780, SEQ ID NO: 9784, SEQ ID NO: 9785, SEQ ID NO: 9795, SEQ ID NO: 9799, SEQ ID NO: 9844, SEQ ID NO: 9872, SEQ ID NO: 9875, SEQ ID NO: 9877, SEQ ID NO: 9878, SEQ ID NO: 9907, SEQ ID NO: 9914, SEQ ID NO: 9920, SEQ ID NO: 9927, SEQ ID NO: 9933, SEQ ID NO: 9940, SEQ ID NO: 10072, SEQ ID NO: 10075, SEQ ID NO: 10076, SEQ ID NO: 10079, SEQ ID NO: 10103, SEQ ID NO: 10192, and SEQ ID NO: 10227.

### Claim 17 (depends on 16)

The immunogenic composition of claim 16, wherein the nucleic acid sequences are contained in a construct for in vivo expression of one or more peptides encoded by the nucleic acid sequences.

### Claim 18 (depends on 17)

The immunogenic composition of claim 17, wherein an administration of the nucleic acid sequences causes the one or more peptides encoded by the nucleic acid sequences to be displayed by an HLA class I molecule in a subject.

### Claim 19 (depends on 17)

The immunogenic composition of claim 17, wherein the nucleic acid sequences are contained in a construct for the in vivo expression of at least two peptides encoded by the nucleic acid sequences, wherein an administration of the nucleic acid sequences causes:
a first peptide of the at least two peptides to be displayed by a first plurality of HLA class I alleles; and
a second peptide of the at least two peptides to be displayed by a second plurality of HLA class I alleles,
wherein the first plurality of HLA class I alleles and the second plurality of HLA class I alleles differ by at least one HLA class I allele.

### Claim 20 (depends on 18)

The immunogenic composition of claim 18, wherein the at least one amino acid sequence comprises two heteroclitic modifications of a fragment of a KRAS protein containing a KRAS G12R mutation.

### Claim 21 (depends on 20)

The immunogenic composition of claim 20, wherein the at least one amino acid sequence is selected based on a HLA class I allele that is expressed in a subject.

### Claim 22 (depends on 16)

The immunogenic composition of claim 16, wherein the nucleic acid sequences encode at least one amino acid sequence selected from the group consisting of SEQ ID NO: 183, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 9760, SEQ ID NO: 9768, SEQ ID NO: 9772, SEQ ID NO: 9775, SEQ ID NO: 9779, SEQ ID NO: 9785, SEQ ID NO: 9799, SEQ ID NO: 9878, SEQ ID NO: 10076, SEQ ID NO: 10103, and SEQ ID NO: 10227.

### Claim 23

An immunogenic composition comprising nucleic acid sequences encoding at least one amino acid sequence selected from the group consisting of SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 8439, SEQ ID NO: 8447, SEQ ID NO: 8464, SEQ ID NO: 8465, SEQ ID NO: 8467, SEQ ID NO: 8468, SEQ ID NO: 8472, SEQ ID NO: 8475, SEQ ID NO: 8498, SEQ ID NO: 8504, SEQ ID NO: 8510, SEQ ID NO: 8513, SEQ ID NO: 8514, SEQ ID NO: 8518, SEQ ID NO: 8524, SEQ ID NO: 8526, SEQ ID NO: 8534, SEQ ID NO: 8554, SEQ ID NO: 8605, SEQ ID NO: 8630, SEQ ID NO: 8631, SEQ ID NO: 8667, SEQ ID NO: 8669, SEQ ID NO: 8671, SEQ ID NO: 8672, SEQ ID NO: 8675, SEQ ID NO: 8704, SEQ ID NO: 8705, SEQ ID NO: 8707, SEQ ID NO: 8708, SEQ ID NO: 8710, SEQ ID NO: 8731, SEQ ID NO: 8733, SEQ ID NO: 8734, SEQ ID NO: 8736, SEQ ID NO: 8764, SEQ ID NO: 8828, SEQ ID NO: 8831, SEQ ID NO: 8841, SEQ ID NO: 8847, SEQ ID NO: 8849, SEQ ID NO: 8851, SEQ ID NO: 8852, SEQ ID NO: 8855, SEQ ID NO: 8863, SEQ ID NO: 8878, SEQ ID NO: 8880, SEQ ID NO: 8882, SEQ ID NO: 8883, SEQ ID NO: 8886, SEQ ID NO: 8898, SEQ ID NO: 8909, SEQ ID NO: 8911, SEQ ID NO: 8913, SEQ ID NO: 8914, SEQ ID NO: 8917, SEQ ID NO: 8958, SEQ ID NO: 9059, SEQ ID NO: 9066, SEQ ID NO: 9067, SEQ ID NO: 9070, SEQ ID NO: 9072, SEQ ID NO: 9073, SEQ ID NO: 9075, SEQ ID NO: 9076, SEQ ID NO: 9083, SEQ ID NO: 9085, SEQ ID NO: 9086, SEQ ID NO: 9103, SEQ ID NO: 9106, SEQ ID NO: 9107, SEQ ID NO: 9112, SEQ ID NO: 9221, SEQ ID NO: 9222, SEQ ID NO: 9279, SEQ ID NO: 9280, SEQ ID NO: 9282, SEQ ID NO: 9286, SEQ ID NO: 9287, SEQ ID NO: 9293, SEQ ID NO: 9336, SEQ ID NO: 9340, SEQ ID NO: 9341, SEQ ID NO: 9345, SEQ ID NO: 9368, SEQ ID NO: 9371, SEQ ID NO: 9375, SEQ ID NO: 9376, SEQ ID NO: 9381, SEQ ID NO: 9393, SEQ ID NO: 9412, SEQ ID NO: 9425, SEQ ID NO: 9458, SEQ ID NO: 9481, SEQ ID NO: 9486, SEQ ID NO: 9491, SEQ ID NO: 9538, SEQ ID NO: 9543, SEQ ID NO: 9544, SEQ ID NO: 9546, SEQ ID NO: 9550, SEQ ID NO: 9551, SEQ ID NO: 9558, SEQ ID NO: 9587, SEQ ID NO: 9591, SEQ ID NO: 9592, SEQ ID NO: 9594, SEQ ID NO: 9598, SEQ ID NO: 9599, SEQ ID NO: 9606, SEQ ID NO: 9626, SEQ ID NO: 9633, SEQ ID NO: 9637, SEQ ID NO: 9642, SEQ ID NO: 9643, SEQ ID NO: 9645, SEQ ID NO: 9649, SEQ ID NO: 9650, SEQ ID NO: 9657, SEQ ID NO: 9698, and SEQ ID NO: 9721.

### Claim 24 (depends on 23)

The immunogenic composition of claim 23, wherein the nucleic acid sequences are contained in a construct for in vivo expression of one or more peptides encoded by the nucleic acid sequences.

### Claim 25 (depends on 24)

The immunogenic composition of claim 24, wherein an administration of the nucleic acid sequences causes the one or more peptides encoded by the nucleic acid sequences to be displayed by an HLA class I molecule in a subject.

### Claim 26 (depends on 24)

The immunogenic composition of claim 24, wherein the nucleic acid sequences are contained in a construct for the in vivo expression of at least two peptides encoded by the nucleic acid sequences, wherein an administration of the nucleic acid sequences causes:
a first peptide of the at least two peptides to be displayed by a first plurality of HLA class I alleles; and
a second peptide of the at least two peptides to be displayed by a second plurality of HLA class I alleles,
wherein the first plurality of HLA class I alleles and the second plurality of HLA class I alleles differ by at least one HLA class I allele.

### Claim 27 (depends on 25)

The immunogenic composition of claim 25, wherein the at least one amino acid sequence comprises two heteroclitic modifications of a fragment of a KRAS protein containing a KRAS G12D mutation.

### Claim 28 (depends on 23)

The immunogenic composition of claim 23, wherein the at least one amino acid sequence is selected based on a HLA class I allele that is expressed in a subject.

### Claim 29 (depends on 23)

The immunogenic composition of claim 23, wherein the nucleic acid sequences encode at least one amino acid sequence selected from the group consisting of SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 8439, SEQ ID NO: 8465, SEQ ID NO: 8851, SEQ ID NO: 8882, SEQ ID NO: 9059, SEQ ID NO: 9067, SEQ ID NO: 9106, SEQ ID NO: 9642, SEQ ID NO: 9698, and SEQ ID NO: 9721.

### Claim 30 (depends on 26)

The immunogenic composition of claim 26, wherein the nucleic acid sequences encode at least two amino acid sequences selected from the group consisting of SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 8439, SEQ ID NO: 8465, SEQ ID NO: 8851, SEQ ID NO: 8882, SEQ ID NO: 9059, SEQ ID NO: 9067, SEQ ID NO: 9106, SEQ ID NO: 9642, SEQ ID NO: 9698, and SEQ ID NO: 9721.
